Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2021

3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

Published 1 July 2021
Categorized as -others, -others, 2021, BT-001, Publication, TG6002

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

Published 28 June 2021
Categorized as 2021, dates, Myvac, Press release, TG4050

First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers

20210624 Transgene TG4001.12 FPI EN

Published 24 June 2021
Categorized as 2021, Press release, TG4001, TG4001

Transgene announces the success of its Capital Increase via a Private Placement

20210622 – Transgene – Pricing PR – ENG – V DEF website

Published 22 June 2021
Categorized as 2021, Press release

Transgene Launches a Capital Increase via a Private Placement

Transgene – Launch CP – ENG – website

Published 21 June 2021
Categorized as 2021, Press release

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)

20210608 – IP Invir.IO ICI – EN

Published 8 June 2021
Categorized as 2021, Invir.IO, Press release

Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors

210527 – Transgene BioInvent_BT001 IND_EN

Published 27 May 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Combined General Meeting of May 26, 2021

20210526 post AG EN

Published 26 May 2021
Categorized as 2021, Press release

Transgene reports business update and end Q1 2021 financial position

20210427 – Transgene – Q1 Financial update EN

Published 27 April 2021
Categorized as 2021, Press release

Transgene Announces Upcoming Investor Meetings

20210412 – Transgene investor agenda EN

Published 12 April 2021
Categorized as 2021, Press release

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu